ClinConnect ClinConnect Logo
Search / Trial NCT06898203

Precision Imaging to Evaluate Kaposi Sarcoma

Launched by WASHINGTON UNIVERSITY SCHOOL OF MEDICINE · Mar 20, 2025

Trial Information

Current as of July 26, 2025

Recruiting

Keywords

Global Oncology Kaposi Sarcoma Affordable Cancer Technologies Cancer In People With Hiv Human Centered Design Discrete Choice Experiment Medical Devices Low Cost Design Global Health

ClinConnect Summary

This clinical trial is focused on improving how doctors measure and track the progress of Kaposi Sarcoma (KS), a common cancer in Uganda and Kenya. Currently, doctors measure the size of cancer spots by hand, which can take a lot of time and may not work well for all patients, especially those with darker skin. The study is testing a new device called SkinScan3D (SS3D) that uses Artificial Intelligence to take accurate measurements of these spots quickly and consistently. The researchers will gather feedback from healthcare workers and patients to make sure the device works effectively in real-life medical settings.

To participate in this trial, you need to be an adult (18 years or older) with confirmed Kaposi Sarcoma and have at least three skin lesions. If you are currently receiving treatment for KS and can give informed consent, you may be eligible. The trial aims to compare the new SS3D device's measurements against the current method and involve about 100 patients. Participants can expect to help shape how this device is used in the future while receiving treatment for their condition.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria - Aim 2 (Patients):
  • Adults age ≥18 years old
  • Histopathology-confirmed Kaposi Sarcoma
  • At least 3 skin lesions
  • Capable of informed consent
  • On treatment for Kaposi Sarcoma
  • Exclusion Criteria - Aim 2 (Patients):
  • Patients not initiating Kaposi Sarcoma treatment
  • Very ill patients requiring hospitalization
  • Inclusion Criteria - Aim 3 (Patients):
  • Adults age ≥18 years old
  • Histopathology-confirmed Kaposi Sarcoma
  • Capable of informed consent
  • Initiating treatment for Kaposi Sarcoma
  • Exclusion Criteria - Aim 3 (Patients):
  • Patients with Kaposi Sarcoma that participated in Aim 1 or Aim 2
  • Prior or ongoing Kaposi Sarcoma treatment

About Washington University School Of Medicine

Washington University School of Medicine is a leading academic medical institution renowned for its commitment to advancing healthcare through innovative research, education, and patient care. With a strong emphasis on translating scientific discoveries into practical applications, the institution conducts a diverse array of clinical trials aimed at improving treatment outcomes and enhancing the understanding of various medical conditions. Its collaborative environment fosters partnerships between researchers, clinicians, and community stakeholders, ensuring that the trials not only contribute to scientific knowledge but also address the pressing health needs of diverse populations.

Locations

Kisumu, , Kenya

Kampala, , Uganda

Patients applied

0 patients applied

Trial Officials

Thomas Odeny, MBChB, MPH, PhD

Principal Investigator

Washington University School of Medicine

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported